Lexicon Pharmaceuticals, Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual filing, not a standalone fourth-quarter report; quarterly figures are noted where useful. The company is a development-stage biopharmaceutical business transitioning toward commercialization. XERMELO was approved by the FDA in February 2017, after year-end, and launched in the United States; accordingly, 2016 included no product-sales revenue.
Financial performance and liquidity
| Metric | 2016 | 2015 | Change / context |
|---|---|---|---|
| Revenue | $83.3 million | $130.0 million | Down 36%; primarily reflects lower Sanofi revenue as the 2015 period included $126.8 million of upfront-payment revenue allocated to the license. |
| Research and development expense | $178.2 million | $95.2 million | Up 87%, mainly from external sotagliflozin development costs. |
| General and administrative expense | $43.0 million | $23.8 million | Up 81%, largely reflecting preparation for XERMELO commercialization. |
| Operating loss | $137.2 million | $1.5 million operating income | Expense growth outweighed collaboration revenue. |
| Net loss | $141.4 million | $4.7 million | Loss per share was $1.36 versus $0.05. |
| Operating cash flow | $(175.6) million | $184.8 million | 2015 benefited from collaboration cash and deferred revenue; 2016 included a $73.3 million decrease in deferred revenue. |
| Cash, cash equivalents and short-term investments | $346.5 million | $521.4 million | Down $174.8 million. |
| Working capital | $193.2 million | $409.4 million | Down substantially year over year. |
| Total debt | $101.4 million | — | $16.3 million mortgage due April 2017 and $85.2 million net long-term debt, principally convertible notes. |
Revenue was highly concentrated: Sanofi represented 90% and Ipsen 9% of 2016 revenue. The filing does not present a useful product gross margin, and product sales had not begun in the reporting year. Fourth-quarter 2016 revenue was $23.0 million and net loss was $32.4 million; fourth-quarter 2015 revenue was $127.3 million and net income was $86.8 million, reflecting the timing of collaboration revenue recognition.
Business developments and material changes
- XERMELO (telotristat ethyl): FDA-approved in February 2017 for carcinoid syndrome diarrhea in adults inadequately controlled on somatostatin analog therapy. U.S. commercialization began after approval. Ipsen holds commercialization rights outside the United States and Japan and had filed for EU approval.
- Sotagliflozin: Two pivotal Phase 3 type 1 diabetes trials met their primary A1C endpoints in top-line results. A third Phase 3 trial was underway; Sanofi was conducting Phase 3 development for type 2 diabetes.
- Other pipeline: LX2761 was in Phase 1 development for diabetes. LX9211 had completed IND-enabling work, with IND submission and clinical development planned.
- R&D spending rose sharply as late-stage sotagliflozin trials advanced. G&A and commercial-readiness spending also increased ahead of the XERMELO launch.
Outlook, risks and contingencies
- Management expected available capital and anticipated collaboration, product and other revenue to fund planned operations for at least 12 months. Planned activities included XERMELO commercialization, completion of the three type 1 diabetes Phase 3 trials, regulatory preparations for sotagliflozin, LX2761 Phase 1 work and initiation of LX9211 clinical development. No product-sales forecast or quantified earnings guidance was provided.
- The company expected substantial continuing losses and R&D and commercialization costs; it stated that future capital needs could require additional financing, which might not be available on acceptable terms.
- Type 1 diabetes sotagliflozin trials showed diabetic ketoacidosis events in treatment arms, including higher incidence at the 400 mg dose than placebo in both reported trials. Full trial results, longer-term safety and the third trial outcome remained outstanding.
- XERMELO’s commercial success depended on market acceptance, reimbursement, pricing, sales execution and supply reliability. The company relied on sole-source manufacturers for finished product and packaging, one logistics provider and two specialty pharmacies.
- The $16.3 million mortgage had a balloon payment due in April 2017; Lexicon said it intended to refinance. Convertible notes carry 5.25% interest and mature in 2021. The filing also describes conversion dilution and potential cash repurchase obligations following a fundamental change.
- A Texas Enterprise Fund job-creation commitment could result in repayment obligations; maximum stated exposure was approximately $14.2 million before credits. A $21.0 million Symphony Icon buyout payment was due upon U.S. XERMELO approval; that approval occurred after year-end.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting. The company reported no material legal proceedings and no significant long-lived-asset impairment in 2016.
Key facts for investors to verify
- Early XERMELO prescription, net sales, payer coverage, pricing and supply performance after the February 2017 launch.
- Final results and safety findings from all three sotagliflozin type 1 diabetes trials, particularly DKA outcomes, and the status of regulatory submissions.
- Sanofi and Ipsen milestone timing, development obligations, royalty economics and the concentration of revenue in these partners.
- Cash burn and liquidity after launch costs, the mortgage refinancing outcome, and the company’s ability to meet debt and other contractual obligations.
- Progress of LX2761 and LX9211, and any changes to management’s stated minimum 12-month funding outlook.